1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Hanall Biopharma Co., Ltd.

Hanall Biopharma Co., Ltd.

009420.KS
Hanall Biopharma Co., Ltd.KR flagKorea Exchange
57,400.00
KRW
+1,800.00
- -
2.92TMarket Cap
Hanall Biopharma Co., Ltd.
009420.KS
(Korea Exchange)

Recent

price

57,400.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3,002.08
2,472.27
2,054.26
1,826.46
2,006.32
1,797.79
1,636.34
1,651.8
1,781.07
2,121.04
1,730.4
1,987.09
2,187.02
2,653.13
2,771.42
3,042.74
3,121.2
Revenue per Share
6
-409.48
-79
-529
-314
-159
40
114
64
375
386
174
5
69
-36
-109
-99.61
Basic EPS, GAAP
-304.97
27
-129.61
-352.95
-176.59
-85.38
-1.6
783.05
-95.29
238.9
-126.17
-159.65
349.68
402.07
-273.43
-322.66
-282.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1,289.94
917.06
863.6
268.1
-51.35
-151.42
-81.89
32.66
49.7
406.64
853.67
1,026.9
1,104.13
1,130.5
1,049.48
926.38
932.48
Book Value per Share
991
856.8
1,488.08
953.56
912.89
1,921.23
1,830.25
1,981.37
2,160.29
2,536.59
3,245.8
2,824.25
2,871.43
3,020.87
2,324.57
1,903.97
1,864.89
Tangible Book Value per Share
36
35
37
41
40
45
51
51
52
51
51
51
50
51
50
51
51
Basic Weighted Avg Shares
106,904
87,702
76,027
74,228
80,880
80,023
82,882
84,231
91,839
108,452
88,602
101,594
109,995
134,910
138,944
155,185
159,065
Sales/Revenue/Turnover
6.4
-7.69
-4.03
-17.49
1.01
-5.35
0.34
4.2
5.96
15.76
6.7
9.94
1.37
1.64
0.17
-0.59
0.2
Operating Margin (%)
1,987
1,800
1,715
1,952
2,260
2,317
2,235
2,162
1,989
2,715
2,894
2,725
3,053
3,247
3,121
3,561
3,499
Depreciation Expense
214
-14,526
-2,924
-21,499
-12,658
-7,077
2,026
5,813
3,300
19,174
19,764
8,896
251
3,509
-1,805
-5,559
-5,077
Net Income, GAAP
87.77
- -
- -
- -
- -
- -
- -
- -
17.42
- -
- -
- -
86.97
- -
- -
- -
107.32
Effective Tax Rate (%)
0.2
-16.56
-3.85
-28.96
-15.65
-8.84
2.44
6.9
3.59
17.68
22.31
8.76
0.23
2.6
-1.3
-3.58
-3.19
Profit Margin (%)
16,908
26,827
44,039
28,369
30,108
78,687
82,043
85,584
106,604
106,910
106,295
96,695
83,254
75,925
50,633
40,445
38,251
Working Capital
8,681
6,795
- -
- -
3,000
- -
- -
- -
- -
201
277
912
751
590
700
15,586
15,587
LT Debt
54,036
50,701
78,670
59,626
45,809
95,216
104,357
111,198
116,918
140,417
181,273
163,492
168,256
186,218
168,351
161,681
162,357
Total Equity
0.83
- -
- -
- -
- -
- -
- -
- -
4
- -
- -
- -
0.12
- -
- -
- -
- -
Return on Invested Capital (%)
0.73
- -
- -
- -
- -
- -
- -
- -
156.1
- -
- -
- -
0.46
- -
- -
- -
3.48
Return on Capital (%)
0.47
-37.02
-9.07
-100.33
- -
- -
- -
- -
156.1
164.2
61.28
18.49
0.47
6.21
-3.28
-11.13
-10.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
704
16,331
28,609
LT Borrowings
- -
15,000
15,000
LT Finance Leases
649
586
587
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
51
51
51
Market Capitalization
1,686,112
2,245,583
2,818,236

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
75,336
84,913
102,082
Cash, Cash Equivalents & STI
11,935
24,743
36,158
Accounts Receivable, Net
16,847
16,869
15,223
Inventories
40,689
38,112
45,465
Total Current Liabilities
37,527
44,468
63,830
Payables & Accruals
- -
- -
- -
ST Debt
704
16,331
28,609
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.07%
-1.95%
-3.96%
Free Cash Flow
-5,041.1%
-83.98%
20.05%
Net Income, GAAP
169.88%
239.93%
208.01%
Sales/Revenue/Turnover
7.43%
12.05%
11.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,094
31,593
36,840
36,417
138,944
2025
36,150
40,682
40,804
37,549
155,185
2026
40,031
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-6
-66
4
- -
-36
2025
-4
11.79
5.82
- -
-109
2026
5.42
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
ScripsAmerica, Inc. (SCRCQ)
Sugi Holdings Co.,Ltd. (7649.T)
NexImmune, Inc. (NEXI)
AllStar Health Brands Inc (ALST)
That Marketing Solution, Inc. (TSTS)
CTT Pharmaceutical Holdings, Inc. (CTTH)
Business
Hanall Biopharma Co., Ltd. (KRX: 009420.KS) is a global biopharmaceutical company that researches, develops, manufactures, and commercializes innovative specialty drugs, biologics, and generics targeting endocrine, circulatory, urologic, immunology, oncology, neurology, ophthalmology, and other therapeutic areas. Founded in 1973 and headquartered in Seoul, South Korea, with additional facilities in Daejeon and operations in the United States, Japan, and Indonesia, the company offers a portfolio of marketed products including Normix for acute enteritis and hyperammonemia; Biotop-D for intestinal regulation and constipation; Eligard for palliative treatment of prostate cancer; and Alphabon for hypocalcemia, tetany, and osteoporosis associated with vitamin D metabolism disorders; alongside antibiotics, amino acid formulations, and other prescription pharmaceuticals sold in South Korea and internationally. Its research and development pipeline features lead candidates such as batoclimab (HL161), a fully human anti-FcRn monoclonal antibody in Phase 3 and Phase 2 trials for myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves' disease; imeroprubart, an advanced FcRn inhibitor in development for cutaneous lupus erythematosus, Sjögren's disease, difficult-to-treat rheumatoid arthritis, and other autoimmune conditions; tanfanercept (HL036), a TNF-alpha inhibitor protein in Phase 3 studies for dry eye disease; and HL192, a Nurr-1 activator for Parkinson's disease. In recent developments, Hanall Biopharma signed an exclusive global licensing agreement with Turn Biotechnologies in 2024 to develop mRNA-based epigenetic reprogramming therapies for age-related eye and ear conditions, valued at over $300 million for the initial product; announced the termination of its HL161 licensing agreement in 2025; received orphan drug designation for batoclimab in Japan; completed a Phase 1 study of HL192 (ATH-399A) with Daewoong Pharmaceutical and NurrOn Pharmaceuticals showing good tolerability; reported Q3 2024 revenue of 36.8 billion KRW; appointed Almira Chabi as Chief Medical Officer and Christopher W. Slavinsky as Chief Business Officer; and continued advancing multiple Phase 3 trials including VELOS-4 for tanfanercept.